A direct inhibitor of HMGB1 cytokine.
HMGB1 and the recently described interleukin-33 (IL-33) are abundant chromatin-associated nuclear factors with potent proinflammatory cytokine activities. In this issue of Chemistry & Biology, Mollica et al. [1] report the identification of the first direct small-molecule inhibitor of HMGB1.
Girard
Jean-Philippe
JP
Laboratory of Vascular Biology, Department of Cancer Biology, Institute of Pharmacology and Structural Biology, IPBS-CNRS UMR 5089, 205 route de Narbonne, 31077 Toulouse, France. Jean-Philippe.Girard@ipbs.fr
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001665:Binding Sites; D019695:Glycyrrhizic Acid / Q000378:metabolism / Q000494:pharmacology; D024243:HMGB1 Protein / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D018836:Inflammation Mediators / Q000378:metabolism; D000067596:Interleukin-33; D007378:Interleukins / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D024243:HMGB1 Protein; C506536:IL33 protein, human; D018836:Inflammation Mediators; D000067596:Interleukin-33; D007378:Interleukins; D019695:Glycyrrhizic Acid